Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Study flowchart and patient flow

Published byθάνα Κουβέλης Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Study flowchart and patient flow"— Presentation transcript:

1 Figure 1 Study flowchart and patient flow
Figure 1 Study flowchart and patient flow. MAE, major arrhythmic event; NIRF, non-invasive risk factors; PEP, primary ... Figure 1 Study flowchart and patient flow. MAE, major arrhythmic event; NIRF, non-invasive risk factors; PEP, primary endpoint (MAE occurrence); PVS, programmed ventricular stimulation—see ‘Methods’ section for more details. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, ehz260, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2 Kaplan–Meier survival curves by risk group
Figure 2 Kaplan–Meier survival curves by risk group. No primary endpoint events occurred in Groups 1 and 2. Patients ... Figure 2 Kaplan–Meier survival curves by risk group. No primary endpoint events occurred in Groups 1 and 2. Patients declining programmed ventricular stimulation are not depicted (unknown risk group). NIRF, non-invasive risk factor. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, ehz260, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Take home figure Outline of study design and findings
Take home figure Outline of study design and findings. Starting with a cohort exhibiting a prevalence of major arrhythmic ... Take home figure Outline of study design and findings. Starting with a cohort exhibiting a prevalence of major arrhythmic events at the 1.5% level (after a 32-month follow-up), the two-step, programmed ventricular stimulation-inclusive approach allowed for the identification of a high arrhythmic risk subgroup with a major arrhythmic event prevalence reaching 22% (almost 15-fold higher than baseline). LP, late potentials; MAE, major arrhythmic event; NIRF, non-invasive risk factors; nsVT, non-sustained ventricular tachycardia; PVC, premature ventricular complex. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, ehz260, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Study flowchart and patient flow"

Similar presentations

Figure 1 Alcohol consumption. A

Figure 1 Alcohol consumption. A
Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
Fig 1 The CONSORT participant flow diagram for primary endpoints.

Fig 1 The CONSORT participant flow diagram for primary endpoints.
Figure 1 Study flow chart.

Figure 1 Study flow chart.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Detection of Bacteriuria by Canine Olfaction

From: Detection of Bacteriuria by Canine Olfaction
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.

Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Figure 1 Study flow diagram and definition of clinical response

Figure 1 Study flow diagram and definition of clinical response
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

Similar presentations

Ads by Google